0.3838
Nanovibronix Inc stock is traded at $0.3838, with a volume of 222.39K.
It is down -0.31% in the last 24 hours and down -23.09% over the past month.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.
See More
Previous Close:
$0.385
Open:
$0.38
24h Volume:
222.39K
Relative Volume:
0.07
Market Cap:
$2.36M
Revenue:
$3.29M
Net Income/Loss:
$-3.09M
P/E Ratio:
-0.312
EPS:
-1.23
Net Cash Flow:
$-2.46M
1W Performance:
-12.77%
1M Performance:
-23.09%
6M Performance:
-38.68%
1Y Performance:
-64.13%
Nanovibronix Inc Stock (NAOV) Company Profile
Name
Nanovibronix Inc
Sector
Industry
Phone
(914) 233-3004
Address
969 PRUITT AVE,, TYLER
Compare NAOV with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NAOV
Nanovibronix Inc
|
0.3838 | 2.36M | 3.29M | -3.09M | -2.46M | -1.23 |
![]()
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Nanovibronix Inc Stock (NAOV) Latest News
NanoVibronix files to sell shares of Series G Convertible Preferred Stock, warrants - MSN
Oncolytics Biotech receives Nasdaq non-compliance notice - MSN
NanoVibronix Completes Merger with ENvue Medical Holdings - TipRanks
NanoVibronix Acquires ENvue Medical Holdings To Expand Medical Device Market Reach - Nasdaq
FDA Approves MED-EL’s Sonnet 3 Audio Processor for Cochlear Implants - MPO-mag
NanoVibronix Acquires Enteral Feeding Company ENvue - MPO-mag
NanoVibronix Acquires ENvue Medical Holdings - citybiz
NanoVibronix Completes ENvue Medical Acquisition -February 14, 2025 at 10:54 am EST - Marketscreener.com
NanoVibronix acquires enteral tech firm ENvue Medical - Investing.com
NanoVibronix completes acquisition of ENvue Medical - TipRanks
NanoVibronix acquires enteral tech firm ENvue Medical By Investing.com - Investing.com UK
Strategic Medical Tech Acquisition: NanoVibronix Takes Over Enteral Feeding Pioneer ENvue - StockTitan
Ascendis Pharma targets €200M SKYTROFA revenue and expands YORVIPATH globally in 2025 - MSN
Ocean Biomedical reports unregistered equity sales - MSN
IMUNON names Douglas Faller as chief medical officer - MSN
Pilot Phase Ends for NanoVibronix’s UroShield Study - MPO-mag
NanoVibronix Provides Year-End Business Update - ACCESS Newswire
NanoVibronix Announces Presentation of PainShield(R) to HCPCS Workgroup at CMS - ACCESS Newswire
NAOV’s 2023 Market Dance: Down -23.05% – Time to Invest? - The InvestChronicle
In the Green: MKDWELL Tech Inc (MKDW) Closes at 0.37, Up/Down -20.43 from Previous Day - The Dwinnex
Market Insights: Oncology Institute Inc (TOI)’s Notable Drop of -3.75, Closing at 0.85 - The Dwinnex
Daily Market Movement: NanoVibronix Inc (NAOV) Sees a -5.63 Decrease, Closing at 0.45 - The Dwinnex
Closing Bell Recap: FMC Corp (FMC) Ends at 35.92, Reflecting a -33.53 Downturn - The Dwinnex
EyePoint stock jumps 10% on Duravyu study results - MSN
Accuray (ARAY) Stock Surges Amidst Market Activity - GuruFocus.com
Whirlpool Corp (WHR) Shares Rise Despite Market Challenges - The News Heater
BBB Foods Inc (TBBB) Stock Price and Analyst Predictions - The News Heater
NAOV’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
NanoVibronix Inc (NAOV) is looking forward to a strong quarter - SETE News
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
NanoVibronix Secures $12M Minimum Purchase Commitment for PainShield - MPO-mag
NanoVibronix Announces Exclusive Agreement for Distribution of PainShield(R) and UroShield(R) in Italy - ACCESS Newswire
NanoVibronix stock touches 52-week low at $0.44 amid market challenges - MSN
NanoVibronix stock touches 52-week low at $0.44 amid market challenges By Investing.com - Investing.com South Africa
NanoVibronix’s UroShield trial results hold potential to advance urinary care: GlobalData - Express Healthcare
NanoVibronix stock touches 52-week low at $0.46 amid market challenges - Investing.com Canada
NanoVibronix stock touches 52-week low at $0.46 amid market challenges By Investing.com - Investing.com South Africa
Septerna (NASDAQ: SEPN) Appoints Gil Labrucherie as Chief Financial Officer - Defense World
NanoVibronix (NASDAQ:NAOV) Enters into Securities Exchange AgreementOn January 7, 2025, NanoVibronix, Inc. filed an 8-K form with the Securities and Exchange Commission, disclosing its recent agreement with an institutional investor. The company en - Defense World
NanoVibronix advances medical device development By Investing.com - Investing.com Canada
NanoVibronix announces exchange agreement with investor By Investing.com - Investing.com
NanoVibronix advances medical device development - Investing.com
NanoVibronix Unveils Next-Gen PainShield and UroShield with Enhanced Therapy Features - StockTitan
Transforming catheter care: NanoVibronix completes successful UroShield US trial - Yahoo Finance
NanoVibronix Announces Completion of Pilot Phase of UroShield® Clinical Study at University of MichiganOn January 6, 2025, NanoVibronix Inc. (NASDAQ: NAOV) revealed the successful conclusion of the initial phase of a Randomized Control Trial study at - Defense World
NanoVibronix Advances UroShield® Trial and Receives Nasdaq Extension - TipRanks
NanoVibronix completes pilot study of UroShield - Mass Device
NanoVibronix “achieves goals” of US trial pilot phase with UroShield - Yahoo Finance
NanoVibronix, Inc. Announces Completion of Pilot Phase of Clinical Study of UroShield at the University of Michigan - Marketscreener.com
Nanovibronix Inc Stock (NAOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):